Rapid-Acting: Insulin Lispro

Rapid-Acting Insulin Lispro Humalog Eli Lilly U-100 15-30 0.5-2.5 3-4 1 0 mL vial, 3 mL cartridge and... 

Ultra-rapid-acting Insulin lispro Human, modified 0.25-0.5 3-4... 

Three rapid-acting insulins have been approved in the United States lispro, aspart, and glulisine. Substitution of one or two amino acids in regular insulin results in the unique pharmacokinetic properties characteristic of these agents. Onset of action of rapid-acting insulins varies from 15 to 30 minutes, with peak effects occurring 1 to 2 hours following administration. 

Rapid-acting insulins Humalog (insulin lispro) Yes Insulin pen 3-mL, vial, and 3-mL pen cartridge... 

Rapid-acting insulin analogues (lispro, insulin aspart [Humalog, Novo log]) have been engineered to contain amino acid modifications that promote rapid entry into the circulation from subcutaneous tissue. They begin to exert their effects as early as 5 to 10 minutes after administration. Lispro insulin, the first insulin analogue to be approved in Europe and the United States, is produced by switching the positions of lysine-proline amino acid residues 28 and 29 of the carboxy terminus of the p-chain. Lispro insulin displays very similar actions to insulin and has a similar affinity for the insulin receptor, but it cannot form stable hexamers or dimers in subcutaneous tissue, which promotes its rapid uptake and absorption. 

Very rapid acting insulin aspart insulin lispro... 

Finally, several commercial preparations are now available that combine two forms of insulin in the same product. Some common examples include preparations that contain a mixture of intermediateacting insulin (e.g., isophane human insulin) and rapid-acting insulin (e.g., regular human insulin, aspart, or lispro). These insulins can be combined in specific amounts such as 50 50, 70 30, or 75 25 ratio of intermediate- to rapid-acting form, depending on the preparation. Products that combine two different forms of insulin can help provide optimal control of blood glucose levels while minimizing the number of injections needed to achieve this control. 

Two rapid-acting insulin analogs are commercially available insulin lispro and insulin aspart. 

Insulin lispro Insulin lispro has a more rapid onset and shorter duration of action than regular human insulin. Therefore, in patients with type 1 diabetes, use in regimens that include a longer-acting insulin. However, in patients with type 2 diabetes, insulin lispro may be used without a longer-acting insulin when used in... 

Ultra-short-acting insulin, very rapid onset, short duration (e.g., lispro insulin)... 

Insulin-Lispro (Humalog) Asn None Lys Pro Thr Rapid acting and peak at 1 hour, instead of 3 hours effect dissipated by 6-8 hours ty2 = 1 hour... 

---